Rafael Cantón
Head of the Microbiology Department at Ramón y Cajal University Hospital (Madrid)
What is your assessment of the results?
“The results provided by the ECDC remain a cause for concern regarding the rise in antimicrobial resistance. They leave little room for optimism regarding the achievement of the targets set by the European Parliament and the European Commission to reduce resistance rates by 2030. Only a slight reduction in antimicrobial consumption is projected, estimated at 5 per cent. In this regard, Spain exceeds the European average and has managed to reduce antimicrobial consumption by 8.2 per cent between 2019 and 2025, with the majority of this reduction occurring in the community setting.”
How do these findings align with the existing evidence?
“The resistance data corroborate scientific publications reporting resistance in local studies and the emergence of increasingly complex microorganisms. These microorganisms harbour more than one resistance mechanism, which even affect the most modern antimicrobials recently brought to market or even those still undergoing clinical trials and in the pre-marketing phase.”
What limitations do these data have when it comes to interpreting the evolution of antibiotic resistance and comparing the situation between countries?
“The data are limited to invasive infections, essentially bacteraemia (blood infection) caused by so-called ‘sentinel’ pathogens and involving a small number of antimicrobials. However, the methodology is similar across all EU countries and associated countries in the European region, so the data are comparable between different countries.”
What does the rise in infections caused by bacteria resistant to last-resort antibiotics, particularly carbapenems, mean?
“It demonstrates that, despite the measures put in place, these are still insufficient – either because they are inadequate or because they are not being implemented. The problem of carbapenem resistance in pathogens such as Klebsiella pneumoniae and, increasingly, in Escherichia coli illustrates the need to strengthen the measures set out in the action plans to combat resistance adopted by all EU countries, some of which are mentioned in the ECDC report (see final questions).”
How does Spain compare with the European Union as a whole? Which trends are of particular concern?
“Spain has made progress in reducing antimicrobial consumption, estimated at just over 8 per cent, with the greatest reduction occurring in the community setting. For the remaining indicators, we are far from meeting the 2030 targets. We have seen an increase in resistance in Escherichia coli to third-generation cephalosporins (around 75 per cent since 2019) and in Klebsiella pneumoniae to carbapenems (nearly 70 per cent since 2019). Europe as a whole has managed to reduce methicillin resistance in Staphylococcus aureus by almost 20 per cent since 2019. However, in Spain it has risen by 5 per cent, further distancing the country from the 2030 target of a 10 per cent reduction in this rate for this pathogen.”
How can we explain that some infections caused by resistant bacteria continue to rise despite the reduction in antibiotic use?
“Antimicrobial use has essentially fallen in the community setting, whilst the indicators analysed (resistant and multidrug-resistant bacteria) are more typical of the hospital setting. Furthermore, the processes by which resistance mechanisms spread amongst bacteria are highly efficient. These cause bacteria to accumulate various mechanisms, leading to the emergence of multidrug-resistant bacteria that are easily selected by different types of antimicrobials. Reducing consumption helps prevent their selection, but this reduction is usually a slower process than the increase.”
What measures should be prioritised to curb these trends and achieve the 2030 European targets? What are the main obstacles in Spain?
“Among these measures, the following would be particularly important for Spain: surveillance and monitoring of consumption and resistance; optimising the use of antimicrobials; raising awareness amongst healthcare professionals and the general public; training for healthcare professionals (including the recognition of infectious diseases as a speciality); continuous support for microbiology laboratories with access to rapid diagnostics, encouraging research networks and the development of new antimicrobials, and improving access to new molecules. It is also important to strengthen epidemiological measures.
The plan to combat antimicrobial resistance has achieved significant successes in Spain, led by the Spanish Agency for Medicines and Health Products (AEMPS), such as the multidisciplinary work of professionals guided by a ‘One Health’ approach, which has successfully reduced the consumption of antimicrobials and led to achievements in the animal sector, with experiences that have been exported to countries in Latin America. However, the lack of funding at national level remains an unresolved issue that limits the measures that can be implemented. Furthermore, improving access to new antimicrobials through initiatives similar to those developed in other countries underscores the need to continue working along these lines in Spain.”